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Deorphaning anti-tuberculosis compounds
using chemogenomic approaches and data from
the ChEMBL database
G. Mugumbate ∗, G. Papadatos, J.P. Overington
EMBL-EBI, Cambridge, United Kingdom
Background: The emergence of drug resistant strains of
Mycobacterium tuberculosis (Mtb), the causative agent of tubercu-
losis (TB), calls for an urgent need for new drugs that have distinct
mechanisms of action. To date, several thousands of active com-
pounds against tuberculosis have been identiﬁed through high
throughput screening (HTS). The challenge then rests identifying
the molecular targets and characterising the mechanism of action
of these actives.
Methods & Materials: We have embarked on applying com-
putational chemogenomics to facilitate identiﬁcation of potential
new TB drug targets. Such methods involve identiﬁcation of poten-
tial targets for new bioactive compounds using chemical space for
bioactive ligands and biological space for their targets [1]. This
has been made possible by use of ChEMBL, which comprises the
largest, freely accessible, primary bioactivity database. The current
release, ChEMBL 17, contains approximately 1.3 million diverse
small molecules along with their biological measurements against
more than 9,000 annotated targets [2]. Speciﬁcally, we analyzed
more than 600,000 target-ligand pairs retrieved from the database.
Multi-categoryNaïve Bayesian classiﬁermodelswere trained using
randomly selected 80% of the target-pairs from the dataset. The
remaining 20% of the pairs were used to validate the models. The
modelswere then employed to predict targets for 25 clinically used
TB drugs, 13 drugs under clinical development, and 773 orphan
anti-TB hits.
Results: The models correctly assigned several validated Mtb
targets to their respective ligands, e.g. ﬂuoroquinolones were pre-
dicted to interactwith the proteinDNAgyrase and alsowith a novel
potential target, Isocitrate lyase. 419 highly ranked target-ligand
pairs contained Mtb proteins and ∼33%, 13%, 5%, of compounds
were assigned kinases, hydrolases, and phosphatases, respectively,
as their potential Mtb targets.
Percentage of compounds assigned to different Mtb protein
families
Conclusion: We have predicted potential targets for the cur-
rent TB drugs and for anti-tuberculosis hits. The results could go a
longway in facilitating reduction of drug resistance and help allevi-
ate the health burden caused by tuberculosis. Follow-up biological
experiments will be carried out in order to validate the predicted
targets.
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Effectivity of Daptomycin therapy in patients
with febrile neutropenia
M. Meric Koc ∗, A. Aynioglu, P. Tarkun
Kocaeli University, Medical Faculty, Kocaeli, Turkey
Background: Daptomycin (DAP) has the most potent in vitro
and bactericidal activity against Gram-positive (G+) pathogens in
comparison to other anti-MRSA agents (vancomycin teicoplanin,
linezolid and tigecycline). Clinical data for DAP in the treatment
of neutropenic patients are limited. The aim of this study was to
evaluate the efﬁcacy of DAP in febrile neutropenic patients.
Methods & Materials: We evaluated data of neutropenic
patients who treated with DAP at Adult Hematology Unit of
our hospital between Jan 2011 and April 2013. Neutropenia was
classiﬁed based on the neutrophil count as severe (<100/mm3),
moderate (101-499/mm3), and mild (500-100/mm3). Clinical out-
comes included cure, improved, failed and nonevaluable response.
Clinical success described patients with an outcome of cure or
improved.
Results: In the study period, 43 neutropenic patients (55.8%
male, median age 50. 8 ± 13.7min: 19 max: 75) who used DAP
were idantiﬁed. All patients had hematological malignancies and
21 (48.8%) patients had severe neutropenia. 40 (93%) patients
received antibiotics prior to DAP therapy, including teikoplanin
(63%), imipenem (49%), piperacillin-tazobactam (40%), others (9%).
Skin and soft tissue infections (%75) was the most common diag-
nosis. G+ organisms were identiﬁed only in 12 patients (27.9%).
Enterococcus feacium was the most common G+ pathogen (7/12).
The initial dose of DAP was 6mg/kg in all patients and the median
duration of therapywas 15.5 days (range 2-45). Overall clinical suc-
cess was 82.5% (33/40). Clinical success rates were 84%, 72%, 90%
in severe, moderate and mild neutropenic patients, respectively.
The success rates in patients receiving daptomycin as ﬁrst-line
therapy was 100% (12/12) compared with 75% (21/28) success
rate in patients who received daptomycin as second-line ther-
apy. Success rates were 83% for bacteraemia and 81% for skin
and soft tissue infection in patients with neutropenia. Dapto-
mycin was well tolerated. No advers event related to DAP was
reported.
Conclusion: Daptomycin was highly effective and safe in the
treatmentG+ infections inneutropenicpatientswithhematological
malignancies.
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